
Patent Law Weblog
recent posts
- Moderna Settles Patent Litigation with Arbutus et al.
- USPTO and DOJ Statement of Interest in Collision Communications: Another Thumb on the Scale in Favor of NPE Patent Plaintiffs
- Oasis Tooling, Inc. v. Siemens Industry Software Inc. (Fed. Cir. 2026)
- Why AI Will Not Take Over the World
- BioNTech Sues Moderna over mRNA Vaccine Technology
about
Category: Inequitable Conduct
-
Pfizer Earns One More Victory in Norvasc Litigation By Robert Dailey — This week Pfizer won another courtroom battle against generic drug manufacturer Synthon in the companies' ongoing dispute over Pfizer's drug Norvasc. The District Court held two Synthon patents, U.S. Patent Nos. 6,653,481 and 6,858,738 unenforceable due to inequitable conduct. Pfizer had…
-
By Donald Zuhn — In an appeal from a District Court judgment holding claims 1-5 of U.S. Patent No. 5,527,814 (the '814 patent) enforceable, valid, and infringed, the Federal Circuit affirmed the District Court's finding of no inequitable conduct, vacated the District Court's finding that claims 1-5 of the '814 patent were not invalid…